Modus Therapeutics AB

https://www.modustx.com

Modus Therapeutics is a Swedish biotech company developing sevuparin for diseases with high unmet medical need with a focus on sickle cell disease (SCD) and malaria. Sevuparin is currently being tested in a Phase II clinical study for SCD – a painful, inherited blood disorder affecting millions of people around the globe. SCD patients’ blood cells form a sickled shape, which makes blood flow to vital organs difficult, causing severe pain and even premature death. Sevuparin has the potential to improve the SCD patients’ blood flow reducing their pain and the amount of time they will need to spend in hospital. Modus plans to develop an administration form of sevuparin that the patient can self-administer allowing them to live a more normal life by preventing the painful episodes requiring hospital care. Modus is predominantly owned by KDev Investments AB, a part of Karolinska Development AB (Nasdaq Stockholm: KDEV) and Rosetta Capital. HealthCap now joins other large owners that include The Foundation for Baltic and European Studies (Östersjöstiftelsen), Ergomed and Praktikerinvest AB. *

	Start	2016-10-20 renamed
	End	2016-10-20 renamed
	Predecessor	Dilaforette AB
	Industry	drug development
	Industry 2	sevuparin
	Person	Donnelly, Ellen K. (Modus Therapeutics 201704– CEO before Pfizer)
	Person 2	Blom, Mats (NorthSea Therapeutics 201909– before Modus Therapeutics + Zealand Pharma + Swedish Orphan International)

	Region	Stockholm
	Country	Sweden
	Street	117 Sankt Eriksgatan
	City	11343 Stockholm
	Tel	+46-70-374-7156
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Modus Therapeutics AB. (7/13/18). "Press Release: Modus Therapeutics Completes a SEK 140 Million Financing Led by HealthCap". Stockholm.

		Record changed: 2024-02-12

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Modus Therapeutics AB

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)